Phaseline

Targets › CD180

CD180 (CD180 antigen): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Pattern recognition receptor predominantly expressed on B-cells, dendritic cells, and certain monocytes/macrophages, structurally resembling Toll-like receptors (TLRs) that plays a role in modulating immune responses. While ressembling a TLR, lacks the intracellular TIR (Toll/IL-1R) signaling domain and thus does not directly transduce signals. (UniProt, Q99467)

Open in Phaseline: the race on CD180, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Hematology & Blood Diseases Hospital, ChinaCD180 CART
anti-CD180 CAR-T cell therapy
CD180Phase 1Acute Myeloid LeukemiaJun 2028

Conditions

Acute Myeloid Leukemia (1)

Modalities

other (1)

Companies

Institute of Hematology & Blood Diseases Hospital, China (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.